TG Therapeutics
TGTX
243 hedge funds and large institutions have $1.38B invested in TG Therapeutics in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 78 increasing their positions, 76 reducing their positions, and 35 closing their positions.
43% more call options, than puts
Call options by funds: $55.2M | Put options by funds: $38.6M
34% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 35
3% more funds holding
Funds holding: 235 → 243 (+8)
3% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 76
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.27% less ownership
Funds ownership: 60.87% → 58.6% (-2.3%)
12% less capital invested
Capital invested by funds: $1.58B → $1.38B (-$190M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$40.1M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$31.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25.8M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$23.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$69.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$37.1M |
| 3 |
Morgan Stanley
New York
|
-$28.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$17.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.8M |
TGTX Hedge Fund Activity: Q1 2024 in Review
243 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2024, worth a combined $1.38B — down 12% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new TGTX positions and 35 closed out — a net gain of 12 holders — while 78 added to existing stakes and 76 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $40.1M. The largest seller was Darwin Global Management, exiting entirely with an estimated $69.1M sold.
- 243 institutional investors held TG Therapeutics (TGTX) as of Q1 2024, up from 235 in Q4 2023.
- Funds reported $1.38B of TG Therapeutics stock for Q1 2024, down 12% quarter-over-quarter.
- 47 funds opened new TG Therapeutics positions in Q1 2024 and 35 closed out, a net change of +12 holders.
- The largest TG Therapeutics buyer in Q1 2024 was Soleus Capital Management, an estimated $40.1M added.
- The largest TG Therapeutics seller in Q1 2024 was Darwin Global Management, an estimated $69.1M sold.
Based on aggregated 13F filings for Q1 2024.